Dudediligence.

Pyxis Oncology, Inc

PYXSNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Dec ’24$2.8MJun ’25$11.0MDec ’25
Net income, by quarter
−$21.2MSep ’24−$35.6MDec ’24−$21.2MMar ’25−$18.4MJun ’25−$22.0MSep ’25−$18.1MDec ’25−$23.3MMar ’26−$25.3MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on filenone on filenone on file$16.1M$13.9M
Gross profitnone on filenone on filenone on file$15.7M$11.5M
Operating income−$69.7M−$123.5M−$82.2M−$89.5M−$84.4M
Net income−$76.0M−$120.7M−$73.8M−$77.3M−$79.6M
Operating cash flow−$35.3M−$89.3M−$70.7M−$57.7M−$63.5M
Free cash flow−$35.9M−$95.7M−$77.4M−$57.9M−$63.5M
Cash$274.7M$179.3M$9.7M$19.5M$15.4M
Shares outstanding32.2M35.0M44.8M60.0M62.7M